Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019

前臨床用画像システム及び試薬の世界市場:光学イメージング装置、核イメージング装置、マイクロMRI、マイクロ超音波、マイクロCT、MPI装置

◆タイトル:Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019
◆商品コード:MAM-MD-3117
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年1月30日
◆ページ数:187
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、前臨床用画像システム及び試薬の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観、産業動向、バリューチェーン分析、市場シェア分析、市場環境分析、システム種類別分析、試薬別分析、地域別分析、市場規模及び予測、競争状況、関連企業分析などの情報をお届けいたします。

The global preclinical imaging market is estimated to grow at a CAGR of 6.0% from 2014 to 2019. Although mature markets (such as the U.S., Germany, France, and the U.K.) hold larger shares in the preclinical imaging market in 2014, the Asia-Pacific region is poised to grow at the highest CAGR of 8.2% in the next five years. Factors such as increased outsourcing of preclinical research activities to Asia-based CROs by big pharmaceutical and biotechnological companies, owing to low cost of research in these nations; and increased government funding for drug discovery and development activities in economically emerging counties are propelling the growth of the preclinical imaging market in Asia-Pacific region.

The growth of the global preclinical imaging market is driven by factors such as development of technologically advanced hybrid preclinical imaging systems such as PET/CT, PET/MRI, and PET/SPECT/CT; growing acceptance of preclinical imaging as a legitimate drug development tool; and rising volume of preclinical research. In addition, emerging markets offering lucrative growth and departure of major companies from preclinical imaging systems market are creating new growth opportunities for the preclinical imaging systems and reagents manufacturers. Nonetheless, declining NIH (National Institutes of Health) funding for life science research, high implementation cost of preclinical imaging devices, and high cost and data requirements for bringing new imaging technology are the key reasons hampering the growth of preclinical imaging market.

In this report, the preclinical imaging market has been segmented on the basis of modality (covering optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic, and magnetic particle imaging systems), by type of reagents (including nuclear imaging reagents, optical imaging reagents, MRIcontrast agents, ultrasound contrast agents and CT contrast agents), and by region (North America, Europe, Asia Pacific, and Rest of the World). The optical imaging systems market is estimated to account for the largest share of the global preclinical imaging systems market in 2014. However, the nuclear imaging systems segment is expected to grow at the highest rate during the forecast period. Factors such as development of technologically advanced hybrid nuclear imaging systems such as PET/MRI and PET/SPECT/CT and rising adoption of these devices in the preclinical research are driving the grow of the preclinical nuclear imaging systems market.

Geographically, North America (comprising the U.S. and Canada) commands the largest share of 36.2% of the global preclinical imaging market in 2014, followed by Europe. The preclinical imaging market in North America is primarily driven by various factors high volume of preclinical research in this region, easy availability and accessibility of resources (such as radioactive tracers), and rising government funding for research and innovation in Canada.
However, declining funding budgets of the U.S. National Institutes of Health (NIH) for preclinical research studies and recent changes in the Canadian R&D tax credit program are negatively affecting the growth of preclinical imaging market in North America.

The global preclinical imaging market is highly fragmented and competitive with a large number of global and local manufacturers of preclinical imaging systems and reagents. As of 2013, the global preclinical imaging market was dominated by PerkinElmer, Inc. (U.S.) and Bruker Corporation (U.S.), which together accounted for ~45% share of the market. New product launches, partnerships, agreements, collaborations, and geographic expansions were the major strategies adopted by most of the market players to achieve growth in the preclinical imaging market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis —industry analysis (industry trends, and Porter’s five force model), market share analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the preclinical imaging systems and reagents market, high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on preclinical imaging products offered by the top 10 players in the preclinical imaging market. The report analyzes the preclinical imaging market by modality and type of reagent across four geographies

• Product Development/Innovation: Detailed insights on current and upcoming technologies, research and development activities, and new product launches in the preclinical imaging market

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various preclinical systems and reagents across geographies

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the preclinical systems and reagents market

• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the preclinical systems and reagents market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 19
1.3.1 LIMITATION 19
1.3.2 MARKETS COVERED 19
1.3.3 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
2.1.1 SECONDARY DATA 22
2.1.1.1 Key Data From Secondary Sources 23
2.1.2 PRIMARY DATA 23
2.1.2.1 Breakdown of Primaries 24
2.1.2.2 Key Data From Primary Sources 24
2.1.2.3 Key Industry Insights 25
2.2 MARKET SIZE ESTIMATION 25
2.2.1.1 Bottom-up Approach 25
2.2.1.2 Top-down Approach 26
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.4 RESEARCH ASSUMPTIONS & LIMITATIONS 29
2.4.1 ASSUMPTIONS 29
2.4.2 LIMITATIONS 29

3 EXECUTIVE SUMMARY 30
3.1 INTRODUCTION 30
3.2 CURRENT SCENARIO 31
3.3 FUTURE OUTLOOK 32
3.4 CONCLUSION 34

4 PREMIUM INSIGHTS 35
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE PRECLINICAL IMAGING MARKET 35
4.2 PRECLINICAL IMAGING REAGENTS MARKETS, BY REGION (2014) 36
4.3 GLOBAL PRECLINICAL IMAGING SYSTEMS, BY REGION (2014) 37
4.4 GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY, (2014–2019) 38

5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET SEGMENTATION 39
5.2.1 BY MODALITY 40
5.2.2 BY REAGENT 41
5.3 MARKET DYNAMICS 41
5.3.1 DRIVERS 42
5.3.1.1 Advancements in molecular imaging technologies 42
5.3.1.2 Growing acceptance of preclinical imaging as a legitimate drug development tool 43
5.3.1.3 Increasing demand for multi-modality imaging technologies in preclinical research 44
5.3.1.4 Increasing number of preclinical research activities 44
5.3.2 RESTRAINTS 45
5.3.2.1 High implementation costs of imaging systems 45
5.3.2.2 Reduced NIH funding for life science research activities 45
5.3.2.3 High cost and data requirements for developing new imaging technologies 46
5.3.3 OPPORTUNITIES 46
5.3.3.1 Emerging markets offer lucrative growth opportunities for market players 46
5.3.3.2 Major companies exiting from the preclinical imaging market is opening new growth avenues for existing market players 47
5.3.3.3 Integration of preclinical MRI systems with other imaging modalities 48
5.3.3.4 Development of low-cost imaging devices with high resolution and sensitivity 48
5.3.4 CHALLENGES 48
5.3.4.1 Technological limitations of standalone preclinical imaging modalities 48
5.3.4.2 Challenges associated with the application of radioisotopes negatively affects the demand of micro-PET systems 49

6 INDUSTRY INSIGHTS 50
6.1 INTRODUCTION 50
6.2 VALUE CHAIN ANALYSIS 50
6.3 SUPPLY CHAIN ANALYSIS 51
6.3.1 KEY STAKEHOLDERS 52
6.3.2 KEY INFLUENCERS 52
6.4 INDUSTRY TRENDS 53
6.4.1 RISING FOCUS OF MARKET PLAYERS TOWARDS THE DEVELOPMENT OF HYBRID PRECLINICAL IMAGING SYSTEMS 53
6.4.2 INCREASING GOVERNMENT FUNDING FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT IN EMERGING NATIONS 53
6.5 PORTER’S FIVE FORCES ANALYSIS 54
6.5.1 THREAT FROM NEW ENTRANTS 54
6.5.2 THREAT FROM SUBSTITUTES 55
6.5.3 BARGAINING POWER OF SUPPLIERS 55
6.5.4 BARGAINING POWER OF BUYERS 56
6.5.5 INTENSITY OF COMPETITIVE RIVALRY 56

7 GLOBAL PRECLINICAL IMAGING MARKET, BY MODALITY 57
7.2 INTRODUCTION 58
7.3 OPTICAL IMAGING SYSTEMS 59
7.3.1 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS 62
7.3.2 STANDALONE FLUORESCENCE IMAGING SYSTEMS 63
7.3.3 OPTICAL + X-RAY/OPTICAL + CT 65
7.4 PRECLINICAL NUCLEAR IMAGING SYSTEMS 66
7.4.1 MICRO-PET SYSTEMS 69
7.4.1.1 Standalone PET Systems 71
7.4.1.2 PET/CT Systems 71
7.4.1.3 PET/MRI Systems 72
7.4.2 MICRO-SPECT SYSTEMS 73
7.4.2.1 Standalone SPECT Systems 74
7.4.2.2 SPECT/CT Systems 75
7.4.2.3 SPECT/MRI Systems 75
7.4.3 TRIMODALITY (SPECT/PET/CT) SYSTEMS 76
7.5 MICRO-MRI 76
7.6 MICRO-ULTRASOUND 78
7.7 MICRO-CT 79
7.8 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS 81
7.9 PRECLINICAL MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS 82

8 GLOBAL PRECLINICAL IMAGING MARKET, BY REAGENTS 83
8.1 INTRODUCTION 84
8.2 PRECLINICAL OPTICAL IMAGING REAGENTS 85
8.2.1 BIOLUMINESCENT IMAGING REAGENTS 87
8.2.1.1 Luciferins 90
8.2.1.1 Proluciferins 90
8.2.1.2 Coelenterazine 91
8.2.1.3 Others 92
8.2.2 FLUORESCENT IMAGING REAGENTS 92
8.2.2.1 Green Fluorescent Proteins 95
8.2.2.2 Red Fluorescent Proteins 95
8.2.2.3 Infrared Dyes 96
8.2.2.4 Others (Natural fluorescence molecules such as Collagen and Elastin) 97

8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS 98
8.3.1 PRECLINICAL PET TRACERS 100
8.3.1.1 Fluorine-18-based Preclinical PET Tracers 101
8.3.1.2 Carbon-11-based Preclinical PET Tracers 102
8.3.1.3 Copper-64-based Preclinical PET Tracers 103
8.3.1.4 Others 103
8.3.2 PRECLINICAL SPECT PROBES 104
8.3.2.1 Technetium-99m-based Preclinical SPECT Probes 106
8.3.2.2 Iodine-131-based Preclinical SPECT Probes 107
8.3.2.3 Gallium-67-based Preclinical SPECT Probes 107
8.3.2.4 Thallium-201-based Preclinical SPECT Probes 108
8.3.2.5 Others 109
8.4 PRECLINICAL MRI CONTRAST AGENTS 109
8.4.1 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS 112
8.4.2 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS 112
8.4.3 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS 113
8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS 114
8.6 PRECLINICAL CT CONTRAST AGENTS 115
8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS 117
8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS 118
8.6.3 GOLD NANOPARTICLES 118
8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS 119

9 GEOGRAPHIC ANALYSIS 120
9.1 INTRODUCTION 121
9.2 NORTH AMERICA 122
9.3 EUROPE 126
9.4 ASIA-PACIFIC 129
9.5 REST OF THE WORLD (ROW) 133

10 COMPETITIVE LANDSCAPE 136
10.1 OVERVIEW 136
10.2 MARKET SHARE ANALYSIS: PRECLINICAL IMAGING MARKET, BY KEY PLAYER, 2013 137
10.3 COMPETITIVE SITUATION AND TRENDS 138
10.3.1 NEW PRODUCT LAUNCHES AND PRODUCT DEVELOPMENTS 139
10.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 140
10.3.3 GEOGRAPHICAL EXPANSIONS 141
10.3.4 MERGERS AND ACQUISITIONS 142
10.3.5 OTHER DEVELOPMENTS 143

11 COMPANY PROFILES 145
11.1 INTRODUCTION 145
11.2 PERKINELMER, INC. 145
11.2.1 BUSINESS OVERVIEW 145
11.2.2 PRODUCT PORTFOLIO 147
11.2.3 KEY STRATEGY 147
11.2.4 KEY DEVELOPMENTS (2012-2014) 148
11.2.5 SWOT ANALYSIS 149
11.3 BRUKER CORPORATION 150
11.3.1 BUSINESS OVERVIEW 150
11.3.2 PRODUCT PORTFOLIO 151
11.3.3 KEY STRATEGY 151
11.3.4 KEY DEVELOPMENTS (2012–2014) 152
11.3.5 SWOT ANALYSIS 153
11.4 FUJIFILM VISUALSONICS, INC. 154
11.4.1 BUSINESS OVERVIEW 154
11.4.2 PRODUCT PORTFOLIO 154
11.4.3 KEY STRATEGY 155
11.4.4 KEY DEVELOPMENTS (2012–2014) 155
11.4.5 SWOT ANALYSIS 156
11.5 MEDISO LTD. 157
11.5.1 BUSINESS OVERVIEW 157
11.5.2 PRODUCT PORTFOLIO 157
11.5.3 KEY STRATEGY 157
11.5.4 KEY DEVELOPMENTS (2012–2014) 158
11.5.5 SWOT ANALYSIS 159
11.6 TRIFOIL IMAGING 160
11.6.1 BUSINESS OVERVIEW 160
11.6.2 PRODUCT PORTFOLIO 160
11.6.3 KEY STRATEGY 161
11.6.4 KEY DEVELOPMENTS (2012–2014) 161
11.7 MR SOLUTIONS LTD. 163
11.7.1 BUSINESS OVERVIEW 163
11.7.2 PRODUCT PORTFOLIO 163
11.7.3 KEY STRATEGY 163
11.7.4 KEY DEVELOPMENTS (2012-2014) 164
11.8 ASPECT IMAGING 165
11.8.1 BUSINESS OVERVIEW 165
11.8.2 PRODUCT PORTFOLIO 165
11.8.3 KEY STRATEGY 165
11.8.4 KEY DEVELOPMENTS (2012–2014) 166
11.9 BIOSPACE LAB S.A. 167
11.9.1 BUSINESS OVERVIEW 167
11.9.2 PRODUCT PORTFOLIO 167
11.9.3 KEY STRATEGY 167
11.9.4 KEY DEVELOPMENTS (2012–2014) 168
11.10 LI-COR BIOSCIENCES 169
11.10.1 BUSINESS OVERVIEW 169
11.10.2 PRODUCT PORTFOLIO 169
11.10.3 KEY STRATEGY 170
11.10.4 KEY DEVELOPMENTS (2012-2014) 170
11.11 MILABS B.V. 172
11.11.1 BUSINESS OVERVIEW 172
11.11.2 PRODUCT PORTFOLIO 172
11.11.3 KEY STRATEGY 173
11.11.4 KEY DEVELOPMENTS (2012–2014) 173

12 APPENDIX 174
12.1 INSIGHTS OF INDUSTRY EXPERTS 174
12.2 DISCUSSION GUIDE* 175
12.3 COMPANY DEVELOPMENTS (2012–2014) 179
12.3.1 ASPECT IMAGING 179
12.3.2 BRUKER CORPORATION 179
12.3.3 LI-COR BIOSCIENCES 180
12.3.4 MEDISO LTD. 182
12.3.5 MILABS B.V. 182
12.3.6 PERKINELMER, INC. 182
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 184
12.5 AVAILABLE CUSTOMIZATIONS 185
12.6 RELATED REPORTS 186

LIST OF TABLES

TABLE 1 PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY,
2012–2019 ($MILLION) 58
TABLE 2 PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 59
TABLE 3 GLOBAL OPTICAL IMAGING SYSTEMS MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 60
TABLE 4 OPTICAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 61
TABLE 5 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS MARKET SIZE,
BY REGION, 2012–2014 ($MILLION) 63
TABLE 6 STANDALONE FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2014 ($MILLION) 64
TABLE 7 OPTICAL + X-RAY/OPTICAL + CT IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2014 ($MILLION) 66
TABLE 8 GLOBAL PRECLINICAL NUCLEAR IMAGING SYSTEMS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 67
TABLE 9 PRECLINICAL NUCLEAR IMAGING SYSTEMS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 68
TABLE 10 GLOBAL MICRO-PET SYSTEMS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 69
TABLE 11 MICRO-PET SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 70
TABLE 12 STANDALONE PET SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 71
TABLE 13 PET/CT SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 72
TABLE 14 PET/MRI SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 72
TABLE 15 GLOBAL MICRO-SPECT SYSTEMS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 73
TABLE 16 MICRO-SPECT SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 74
TABLE 17 STANDALONE SPECT SYSTEMS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 74
TABLE 18 SPECT/CT SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 75
TABLE 19 MICRO-MRI SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 77
TABLE 20 MICRO-ULTRASOUND SYSTEMS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 79
TABLE 21 MICRO-CT SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 80
TABLE 22 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 82
TABLE 23 GLOBAL PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 84
TABLE 24 PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 85
TABLE 25 GLOBAL PRECLINICAL OPTICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 86
TABLE 26 PRECLINICAL OPTICAL IMAGING REAGENTS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 87
TABLE 27 GLOBAL PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE,
BY TYPE, 2012–2019 ($MILLION) 88
TABLE 28 PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 89
TABLE 29 PRECLINICAL LUCIFERINS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 90
TABLE 30 PRECLINICAL PROLUCIFERINS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 91
TABLE 31 PRECLINICAL COELENTERAZINE MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 91
TABLE 32 OTHER PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE,
BY REGION, 2012–2019 ($MILLION) 92
TABLE 33 GLOBAL PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 93
TABLE 34 PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 94
TABLE 35 PRECLINICAL GREEN FLUORESCENT PROTEINS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 95
TABLE 36 PRECLINICAL RED FLUORESCENT PROTEINS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 96
TABLE 37 PRECLINICAL INFRARED DYES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 97
TABLE 38 OTHER PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE,
BY REGION, 2012–2019 ($MILLION) 97
TABLE 39 GLOBAL PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 98
TABLE 40 PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 99
TABLE 41 GLOBAL PRECLINICAL PET TRACERS MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 101
TABLE 42 PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 101
TABLE 43 FLUORINE-18-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 102
TABLE 44 CARBON-11-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 102
TABLE 45 COPPER-64-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 103
TABLE 46 OTHER PRECLINICAL PET TRACERS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 104
TABLE 47 GLOBAL PRECLINICAL SPECT PROBES MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 105
TABLE 48 PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 106
TABLE 49 TECHNETIUM-99M-BASED PRECLINICAL SPECT PROBES MARKET SIZE,
BY REGION, 2012–2019 ($MILLION) 106
TABLE 50 IODINE-131-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 107
TABLE 51 GALLIUM-67-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 108
TABLE 52 THALLIUM-201-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 108
TABLE 53 OTHER PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 109
TABLE 54 GLOBAL PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 110
TABLE 55 PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 111
TABLE 56 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE,
BY REGION, 2012–2019 ($MILLION) 112
TABLE 57 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 113
TABLE 58 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE,
BY REGION, 2012–2019 ($MILLION) 113
TABLE 59 PRECLINICAL ULTRASOUND CONTRAST AGENTS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 115
TABLE 60 GLOBAL PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY TYPE,
2012–2019 ($MILLION) 116
TABLE 61 PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 117
TABLE 62 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 117
TABLE 63 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 118
TABLE 64 GOLD NANOPARTICLES PRECLINICAL CT CONTRAST AGENTS MARKET SIZE,
BY REGION, 2012–2019 ($MILLION) 119
TABLE 65 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE,
BY REGION, 2012–2019 ($MILLION) 119
TABLE 66 GLOBAL PRECLINICAL IMAGING SYSTEMS AND REAGENTS MARKET SIZE,
BY REGION, 2012-2019 ($MILLION) 122
TABLE 67 NORTH AMERICA: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT,
2012-2019 ($MILLION) 124
TABLE 68 NORTH AMERICA: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2012-2019 ($MILLION) 125
TABLE 69 U.S.: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY,
2012-2019 ($MILLION) 125
TABLE 70 NORTH AMERICA: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 126
TABLE 71 EUROPE: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT,
012-2019 ($MILLION) 128
TABLE 72 EUROPE: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY,
2012-2019 ($MILLION) 129
TABLE 73 EUROPE: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE,
2012-2019 ($MILLION) 129
TABLE 74 ASIA-PACIFIC: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT,
2012-2019 ($MILLION) 132
TABLE 75 ASIA-PACIFIC: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2012-2019 ($MILLION) 132
TABLE 76 ASIA-PACIFIC: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE,
2012-2019 ($MILLION) 133
TABLE 77 ROW: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2012-2019 ($MILLION) 134
TABLE 78 ROW: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY,
2012-2019 ($MILLION) 134
TABLE 79 ROW: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE,
2012-2019 ($MILLION) 135
TABLE 80 TOP 5 NEW PRODUCT LAUNCHES AND PRODUCT DEVELOPMENTS, 2012–2014 139
TABLE 81 TOP 5 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2012–2014 140
TABLE 82 TOP 5 GEOGRAPHICAL EXPANSIONS, 2012–2014 141
TABLE 83 MERGERS AND ACQUISITIONS, 2012–2014 142
TABLE 84 TOP 5 OTHER DEVELOPMENTS, 2012–2014 144


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 22
FIGURE 2 BREAK DOWN OF SUPPLY SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 24
FIGURE 3 PRECLINICAL IMAGING SYSTEMS MARKET: BOTTOM UP APPROACH 26
FIGURE 4 PRECLINICAL IMAGING SYSTEMS MARKET: TOP-DOWN APPROACH 26
FIGURE 5 PRECLINICAL IMAGING REAGENTS MARKET: TOP-DOWN APPROACH 27
FIGURE 6 PRECLINICAL IMAGING MARKET: DATA TRIANGULATION 28
FIGURE 7 GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, 2014 ($MILLION) 30
FIGURE 8 GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY, 2014 VS. 2019 32
FIGURE 9 GLOBAL PRECLINICAL IMAGING REAGENTS MARKET, 2014 VS. 2019 33
FIGURE 10 GLOBAL PRECLINICAL IMAGING MARKET, BY REGION, 2014 ($MILLION) 34
FIGURE 11 EMERGING COUNTRIES OFFERING HIGH GROWTH OPPORTUNITIES TO PLAYERS IN THE PRECLINICAL IMAGING MARKET 35
FIGURE 12 NORTH AMERICA COMMANDS THE LARGEST SHARE OF THE GLOBAL PRECLINICAL IMAGING REAGENTS MARKET 36
FIGURE 13 OPTICAL, NUCLEAR, MRI, & ULTRASOUND IMAGING SYSTEMS COMMAND THE LARGEST SHARE OF THE GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET 37
FIGURE 14 OVER 80% OF THE GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET WILL BE DOMINATED BY OPTICAL, NUCLEAR, & MRI SYSTEMS IN 2019 38
FIGURE 15 PRECLINICAL IMAGING MARKET SEGMENTATION 39
FIGURE 16 PRECLINICAL IMAGING MARKET SEGMENTATION, BY MODALITY 40
FIGURE 17 PRECLINICAL IMAGING REAGENTS MARKET SEGMENTATION, BY TYPE 41
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 42
FIGURE 19 ADVANCEMENTS IN MOLECULAR IMAGING TECHNOLOGIES BOOSTING THE ADOPTION OF THESE SYSTEMS IN PRECLINICAL RESEARCH STUDIES 44
FIGURE 20 HIGH COST OF IMAGING SYSTEMS AND REDUCED NIH FUNDING ARE RESTRICTING THE GROWTH OF PRECLINICAL IMAGING MARKET 46
FIGURE 21 EMERGING ECONOMIES OFFERING HIGH GROWTH POTENTIAL FOR PRECLINICAL IMAGING MARKET 47
FIGURE 22 TECHNOLOGICAL LIMITATIONS OF INDIVIDUAL IMAGING MODALITIES IS A KEY GROWTH CHALLENGE FOR STANDALONE PRECLINICAL IMAGING DEVICE PROVIDERS 49
FIGURE 23 VALUE CHAIN OF PRECLINICAL IMAGING SYSTEMS MARKET 51
FIGURE 24 MARKET PLAYERS PREFER BOTH DIRECT & INDIRECT DISTRIBUTION STRATEGIES 52
FIGURE 25 PORTER’S FIVE FORCES ANALYSIS, 2014 54
FIGURE 26 PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY, 2014 VS. 2019 ($MILLION): NUCLEAR IMAGING SYSTEMS MARKET TO GROW AT
THE FASTEST RATE 58
FIGURE 27 THE BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS SEGMENT HOLDS A MAJOR SHARE OF THE PRECLINICAL OPTICAL IMAGING SYSTEMS MARKET (2014) 60
FIGURE 28 THE ASIA-PACIFIC PRECLINICAL OPTICAL IMAGING SYSTEMS MARKET IS EXPECTED TO GROW AT A HIGH RATE FROM 2014 TO 2019 61
FIGURE 29 THE ASIA-PACIFIC PRECLINICAL BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS MARKET IS EXPECTED TO GROW AT A DOUBLE DIGIT RATE DURING THE FORECAST PERIOD 62
FIGURE 30 THE STANDALONE FLUORESCENCE IMAGING SYSTEMS MARKET IS EXPECTED TO WITNESS SLUGGISH GROWTH IN ALL GEOGRAPHIC REGIONS 64
FIGURE 31 DEMAND FOR OPTICAL + X-RAY/OPTICAL + CT IMAGING SYSTEMS IS EXPECTED TO GROW RAPIDLY IN THE ASIA-PACIFIC REGION 65
FIGURE 32 THE MICRO-PET SYSTEMS SEGMENT HOLDS THE LARGEST SHARE OF THE PRECLINICAL NUCLEAR IMAGING SYSTEMS MARKET IN 2014 67
FIGURE 33 NORTH AMERICA COVERS THE LARGEST SHARE OF THE PRECLINICAL NUCLEAR IMAGING SYSTEMS MARKET IN 2014 68
FIGURE 34 PET/MRI SYSTEMS MARKET IS EXPECTED TO GROW AT A DOUBLE-DIGIT RATE DURING THE FORECAST PERIOD 69
FIGURE 35 ASIA-PACIFIC IS EXPECTED TO OUTPACE THE EUROPEAN MICRO-PET SYSTEMS MARKET BY 2019 70
FIGURE 36 NORTH AMERICA WILL CONTINUE TO DOMINATE THE MICRO-SPECT SYSTEMS MARKET IN THE NEXT FIVE YEARS 73
FIGURE 37 THE ASIA-PACIFIC MICRO-MRI SYSTEMS MARKET IS EXPECTED TO EQUAL THE MARKET SIZE OF THE NORTH AMERICAN MARKET BY 2019 77
FIGURE 38 NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL MICRO-ULTRASOUND SYSTEMS MARKET BY 2019 78
FIGURE 39 NORTH AMERICA HOLDS THE LARGEST SHARE OF THE GLOBAL MICRO-CT SYSTEMS MARKET IN 2014 80
FIGURE 40 NORTH AMERICA IS EXPECTED TO BE THE SECOND-FASTEST-GROWING MARKET FOR PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS AFTER ASIA-PACIFIC DURING THE FORECAST PERIOD 81
FIGURE 41 GLOBAL PRECLINICAL IMAGING REAGENTS MARKET, 2014 VS. 2019 ($MILLION): MRI CONTRAST AGENTS MARKET TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 84
FIGURE 42 BIOLUMINESCENT IMAGING REAGENTS SEGMENT WILL CONTINUE TO DOMINATE THE PRECLINICAL OPTICAL IMAGING REAGENTS MARKET IN THE FORECAST PERIOD 85
FIGURE 43 ASIA-PACIFIC PRECLINICAL OPTICAL IMAGING REAGENTS MARKET IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE NEXT FIVE YEARS 86
FIGURE 44 LUCIFERINS TO COMMAND THE LARGEST SHARE OF BIOLUMINESCENT IMAGING REAGENTS MARKET IN 2014 88
FIGURE 45 ASIA-PACIFIC REGION IS ESTIMATED TO WITNESS THE HIGHEST GROWTH RATE IN THE BIOLUMINESCENT IMAGING REAGENTS MARKET 89
FIGURE 46 INFRARED DYES ACCOUNT FOR THE LARGEST SHARE OF PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET IN 2014 93
FIGURE 47 ASIA-PACIFIC AND ROW REGIONS WILL DRIVE THE GROWTH OF PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET DURING THE FORECAST PERIOD 94
FIGURE 48 PET TRACERS WILL CONTINUE TO DOMINATE THE PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET IN THE NEXT FIVE YEARS 98
FIGURE 49 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE GLOBAL PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET IN 2014 99
FIGURE 50 FLUORINE-18-BASED PET TRACERS COMMAND THE LION’S SHARE OF PRECLINICAL PET TRACERS MARKET IN 2014 100
FIGURE 51 TECHNETIUM-99M-BASED SPECT PROBES COMMAND THE LION’S SHARE OF PRECLINICAL SPECT PROBES MARKET IN 2014 105
FIGURE 52 GADOLINIUM-BASED MRI CONTRAST AGENTS COMMAND THE LARGEST SHARE OF PRECLINICAL MRI CONTRAST AGENTS MARKET IN 2014 110
FIGURE 53 ASIA-PACIFICA MRI CONTRAST AGENTS MARKET IS ESTIMATED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 111
FIGURE 54 NORTH AMERICA ACCOUNTS FOR THE MAJOR SHARE OF THE PRECLINICAL ULTRASOUND CONTRAST AGENTS MARKET IN 2014 114
FIGURE 55 IODINE-BASED CONTRAST AGENTS HOLD THE LARGEST SHARE OF PRECLINICAL CT CONTRAST AGENTS MARKET IN 2014 116
FIGURE 56 PRECLINICAL IMAGING MARKET, BY REGION, 2014 VS. 2019 ($MILLION): ASIA-PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 121
FIGURE 57 NORTH AMERICAN PRECLINICAL IMAGING MARKET SNAPSHOT (2014-2019): GROWTH IS DRIVEN BY HIGH ADOPTION OF INNOVATIVE TECHNOLOGIES 123
FIGURE 58 EUROPEAN PRECLINICAL IMAGING MARKET SNAPSHOT (2014-2019): GROWTH IS DRIVEN BY INCREASED GOVERNMENT FUNDING FOR DEVELOPING EUROPEAN RESEARCH SECTOR 127
FIGURE 59 ASIA-PACIFIC PRECLINICAL IMAGING MARKET SNAPSHOT (2014-2019): GROWTH IS DRIVEN BY RISING GOVERNMENT INVESTMENT IN PHARMACEUTICAL R&D 130
FIGURE 60 LEADING MARKET PLAYERS ADOPTED NEW PRODUCT LAUNCHES AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS (2012–2014) 136
FIGURE 61 GLOBAL PRECLINICAL IMAGING MARKET SHARE, BY KEY PLAYER, 2013 137
FIGURE 62 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES IS THE KEY STRATEGY 138
FIGURE 63 PRECLINICAL IMAGING SYSTEMS PORTFOLIO MIX OF TOP 5 MARKET PLAYERS 145
FIGURE 64 PERKINELMER, INC.: COMPANY SNAPSHOT 146
FIGURE 65 BRUKER CORPORATION: COMPANY SNAPSHOT 150
FIGURE 66 FUJIFILM HOLDINGS CORPORATION.: COMPANY SNAPSHOT 154


【レポートのキーワード】

前臨床用画像システム、光学イメージング装置、核イメージング装置、マイクロMRI、マイクロ超音波、マイクロCT、光音響イメージング装置、MPI装置、医療機器、試薬

★調査レポート[前臨床用画像システム及び試薬の世界市場:光学イメージング装置、核イメージング装置、マイクロMRI、マイクロ超音波、マイクロCT、MPI装置] ( Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019 / MAM-MD-3117) 販売に関する免責事項
[前臨床用画像システム及び試薬の世界市場:光学イメージング装置、核イメージング装置、マイクロMRI、マイクロ超音波、マイクロCT、MPI装置] ( Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019 / MAM-MD-3117) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆